Vivos Therapeutics Secures $2.1M in Dilutive Equity Financing to Address Liquidity Needs
VVOS sits 19% above its 52-week low of $0.383 on light trading volume (0.1× avg).
Summary
Vivos Therapeutics raised $2.1 million through a private placement of convertible preferred stock and warrants, including $1 million in new cash and $1 million from debt conversion, to fund general working capital.
Key Events · Financing and Capital Events · VVOS
-
Secured $2.1 Million Equity Financing
The company entered into a Securities Purchase Agreement to sell 3,608,496 units at $0.582 per unit, totaling approximately $2.1 million. This includes $1 million in new cash proceeds and the conversion of a $1 million bridge promissory note.
-
Dilutive Structure with Preferred Stock and Warrants
Each unit consists of one share of Series A Convertible Preferred Stock (convertible 1:1 into common stock at a stated value of $0.456) and warrants to purchase an equal number of common shares (exercise price $0.456). The preferred stock conversion ratio is fixed, not subject to price-based resets.
-
Addresses Critical Working Capital Needs
The net proceeds are designated for general working capital, which is crucial for the company given its recent 'going concern' warning and Nasdaq non-compliance notice.
-
CEO Participation and Pricing Above Market
R. Kirk Huntsman, Chairman and CEO, indirectly participated with approximately $50,000. The preferred stock and warrant exercise prices are slightly above the current market price of $0.455, which is a positive signal for a distressed company.
Analysis · VVOS · Industrial Applications And Services
Vivos Therapeutics, a company facing a 'going concern' warning and Nasdaq delisting risk, has secured a critical $2.1 million in equity financing. This capital raise, while highly dilutive, provides essential working capital and includes the conversion of $1 million in existing debt, extending the company's financial runway. The pricing of the preferred stock and warrants slightly above the current market price, along with indirect participation from the CEO, suggests a degree of confidence in the company's future despite its distressed state. The fixed conversion ratio for the preferred stock also avoids more punitive 'death spiral' financing terms often seen in such situations.
At the time of this filing, VVOS was trading at $0.46 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $6.7M. The 52-week trading range was $0.38 to $7.95. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.